Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.